Compare PulteGroup, Inc. (PHM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs BIO-TECHNE Corp — how do they compare? PulteGroup, Inc. trades at $113.37 (market cap $21.63B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: PulteGroup, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays the higher dividend (0.92%). Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and BIO-TECHNE Corp for 63 Days on average.
| PHM | TECH | |
|---|---|---|
Market Cap | $21.63B | $11.36B |
Volume | 2,324,729 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $72.61 |
52-Week Low | $110.11 | $43.31 |
Typical Hold Time | 91 Days | 63 Days |
Enterprise Value | $22.04B | $11.39B |
Dividend Yield | 0.92% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $112.33, down 3.25% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with recent earnings misses but maintains solid fundamentals including an 11.47 P/E ratio and 14.9% ROE. Cash flow remains positive at $355 million for 2025, though revenue and margins have softened from 2024 peaks. The company continues dividend payments with a $0.26 quarterly payout scheduled for October 2026.
PHM presents a mixed outlook with attractive valuation metrics offset by near-term headwinds. The consensus price target of $139.80 suggests 24% upside potential, but rising interest rates pose significant risk to housing demand. Investors face tension between Wall Street's bullish price targets and current technical weakness, requiring careful monitoring of Q3 2026 earnings due October 22nd for directional clarity.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
